Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-12-01T04:58:57.008Z Has data issue: false hasContentIssue false
  • English
  • Français

Mechanism of action of the SPARI vilazodone: serotonin 1A partial agonist and reuptake inhibitor

Published online by Cambridge University Press:  28 March 2014

Stephen M. Stahl
Get access Rights & Permissions [Opens in a new window]

Abstract

ISSUE:Vilazodone is an antidepressant with a novel mechanism of pharmacologic action: serotonin partial agonist reuptake inhibitor (SPARI).

Type
Brainstorms
Information
CNS Spectrums , Volume 19 , Issue 2 , April 2014 , pp. 105 - 109
Copyright
Copyright © Cambridge University Press 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Stahl, SM. Stahl's Essential Psychopharmacology, 4th ed. New York: Cambridge University Press; 2013.Google Scholar
2. Bartoszky, GD, Hegenbart, R, Zielger, H. EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5HT1A receptor agonistic properties. Eur J Pharmacol. 1997; 322(2–3): 147–153.Google Scholar
3. Hughes, ZA, Starr, KR, Langmead, CJ, etal. Neurochemical evaluation of the novel 5HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol. 2005; 510(1–2): 49–57.Google Scholar
4. Page, ME, Cryan, JF, Sullivan, A, etal. Behavioral and neurochemical effects of 5-(4-(4-(5-cyano-3-indolyl)-butyl)-butyl)-1-piperazinyl)benzofuran-2-carboxamine (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine 1A receptor partial agonist. J Pharmacol Exp Ther. 2002; 302(3): 1220–1227.Google Scholar
5. Stahl, SM. Classifying psychotropic drugs by mode of action and not by target disorder. CNS Spectr. 2013; 18(3): 113–117.Google Scholar
6. Rabiner, EA, Gunn, RN, Wilkins, MR, etal. Drug action at the 5HT1A receptor in vivo: autoreceptor and postsynaptic receptor occupancy examined with PET and (carbonyl-(11)C)WAY-100635. Nucl Med Biol. 2000; 27(5): 509–513.Google Scholar
7. Rickels, K, Athanasious, M, Robinson, DS, etal. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009; 70(3): 326–333.Google Scholar
8. Khan, A, Cutler, AJ, Kajdasz, DK, etal. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry. 2011; 72(4): 441–447.Google Scholar
9. Schwartz, TL, Siddiqui, UA, Stahl, SM. Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor. Ther Adv Psychopharmacol. 2011; 1(3): 81–87.Google Scholar